|
|
|
|
| LEADER |
02659nam a22003495i 4500 |
| 001 |
000293613 |
| 005 |
20210610143811.0 |
| 007 |
cr nn 008mamaa |
| 008 |
140916s2014 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319067520
|
| 024 |
7 |
|
|a 10.1007/978-3-319-06752-0
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Resistance to Proteasome Inhibitors in Cancer :
|b Molecular Mechanisms and Strategies to Overcome Resistance /
|c edited by Q. Ping Dou.
|
| 250 |
|
|
|a 1st ed. 2014.
|
| 260 |
# |
# |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2014.
|
| 300 |
|
|
|a XI, 390 p. 55 illus., 51 illus. in color. :
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Resistance to Targeted Anti-Cancer Therapeutics,
|
| 505 |
0 |
|
|a Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer -- Resistance to proteasome inhibitors in multiple myeloma -- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma -- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis -- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy -- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition -- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies -- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches -- Targeting the proteasome pathway for the treatment of solid tumors -- Oxidative stress and the proteasome: mechanism and the therapeutic relevance -- Proteotoxic stress and proteasome inhibitor efficacy and resistance -- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy -- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2) -- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies -- Deubiquitinating enzymes as novel targets for cancer therapies.
|
| 650 |
|
0 |
|a Cancer research.
|
| 650 |
|
0 |
|a Drug resistance.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Molecular biology.
|
| 650 |
1 |
4 |
|a Cancer Research.
|
| 650 |
2 |
4 |
|a Drug Resistance.
|
| 650 |
2 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Molecular Medicine.
|
| 700 |
1 |
|
|a Dou, Q. Ping.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|